The latter is currently in clinical trials (Phase II) in recurrent GBMs (NCT00980343) and (Phase I/II) in patients with newly diagnosed GBM without O6 methylguanine methyl transferase (MGMT) promoter methylation (NCT03158389, referred below as N2M2 (NOA-20), NCT Neuro Master Match the umbrella protocol for Phase I/IIa trials of molecularly matched targeted therapies combined with RT) [71]. Here, MGMT is linked to glioblastoma.